Craig-Hallum analyst William Bonello maintained a Buy rating on GeneDx Holdings (WGS – Research Report) today. The company’s shares closed ...

STAMFORD, Conn. - GeneDx Holdings Corp. (NASDAQ:WGS), known for its genomic insights in healthcare and having achieved an impressive 2,342% return over the past year according to InvestingPro data ...

January 13, 2025--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for ...

--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq ... described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the ...

January 13, 2025--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for the ...

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a new way to provide genetic counseling and test-ordering services for patients and ...

"GeneDx understands that a genetic diagnosis can be life-changing for families, offering crucial insights that inform personalized care and treatment, which can lead to significantly improved ...

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a new way to provide genetic counseling and ...

BTIG Life Sciences and Diagnostic Tools Analyst Massaro holds group dinner meeting with CEO Stueland and CFO Feeley on January 13 at 10:30 am. Discover outperforming stocks and invest smarter with ...

On Tuesday, TD Cowen exhibited confidence in GeneDx (NASDAQ: WGS), significantly raising the stock's price target from $75.00 to $118.00 while maintaining a Buy rating. The firm's analyst highlighted ...